Page last updated: 2024-12-11
entadamide a
Description
entadamide A: structure given in first source; RN refers to (E)-isomer; isolated from Entada phaseoloides [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|
| Entada | genus | [no description available] | Fabaceae | The large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH] |
| Entada phaseoloides | species | [no description available] | Fabaceae | The large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH] |
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 6439215 |
| CHEMBL ID | 2235398 |
| CHEBI ID | 179370 |
| SCHEMBL ID | 18297867 |
| SCHEMBL ID | 18297864 |
| MeSH ID | M0170787 |
Synonyms (16)
| Synonym |
|---|
| 100477-88-1 |
| CHEBI:179370 |
| (e)-n-(2-hydroxyethyl)-3-methylsulanylprop-2-enamide |
| entadamide a |
| (e)-n-(2-hydroxyethyl)-3-methylsulfanylprop-2-enamide |
| C20204 |
| 2-propenamide, n-(2-hydroxyethyl)-3-(methylthio)-, (e)- |
| n-(2-hydroxyethyl)-3-methylthiopropenamide |
| c6h11no2s |
| entadamide |
| CHEMBL2235398 |
| SCHEMBL18297867 |
| SCHEMBL18297864 |
| E88912 |
| FS-7332 |
| AKOS040736470 |
Drug Classes (1)
| Class | Description |
|---|
| N-acylethanolamine | An ethanolamine substituted at nitrogen by an acyl group. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.94
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.94 (24.57) | | Research Supply Index | 1.95 (2.92) | | Research Growth Index | 4.88 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (16.67%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (83.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |